Naval Daver

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Naval Daver
Apr 29, 2025, 09:33 | Blog
Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University…
Apr 18, 2025, 17:19 | Insight
MD Anderson Research Highlights
Insights into AML, overcoming radiotherapy resistance, and new treatment strategies for patients with blood cancers…
Mar 11, 2025, 08:03 | Drugs
Naveen Pemmaraju: Bromodomain and PLX51107 with Azacitidine in Patients with R/R Myeloid Malignancies
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University…
Dec 26, 2024, 14:37 | Insight
Jayastu Senapati: Largest reported cohort in secondary AML
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “Check…
Dec 13, 2024, 05:16 | Insight
MD Anderson Research Highlights: ASH 2024 Special Edition
Featuring novel treatments and research insights for MDS, leukemia, and lymphoma, encouraging long-term trial data,…
Dec 5, 2024, 16:20 | Insight
ASH24 studies from MD Anderson presented by Jayastu Senapati
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “ASH24…
Dec 2, 2024, 19:24 | Insight
Naveen Pemmaraju: PVO combination program for frontline CLL treatment
Naveen Pemmaraju shared a post on X: '' ASH Kudos to Dr. Nitin Jain for an…
Nov 20, 2024, 14:44 | Insight
Talha Badar: What we have learned about TP53-mutated AML?
Talha Badar, Hematology/Oncology specialist in Mayo Clinic, shared an article by Moazzam Shahzad on X:…
Oct 1, 2024, 11:05 | Blog,Insight
Mohamed Benlazar: General approach to patients with AML
Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on…
Sep 26, 2024, 15:39 | Insight
Article of the Week, Suggested by the BPDCN International Registry
Immune Oncology Research Institute shared a post on LinkedIn: "Article of the Week Suggested by the…
Sep 21, 2024, 10:29 | Blog
Charlie Craddock: Future trial opportunities in AML
Charlie Craddock, Physician, Queen Elizabeth Hospital shared a post by Joshua Zeidner, Associate Professor Of Medicine,…
Sep 11, 2024, 09:16 | Insight
Naveen Pemmaraju: Pivekimab sunirine in relapsed or refractory acute myeloid leukaemia
Naveen Pemmaraju shared a post on X about a recent paper by Naval Daver et…
Jul 23, 2024, 22:30 | Blog
Hagop Kantarjian: The simultaneous combination of ponatinib and blinatumomab highly effective
Hagop Kantarjian shared on X: "The simultaneous combination of ponatinib and blinatumomab highly effective: MRD-negativity rate…
Jul 20, 2024, 14:27 | Insight
Naveen Pemmaraju: Important paper on AML and Hyperleukocytosis
Naveen Pemmaraju shared a post about a paper titled "Outcomes of Patients With Newly Diagnosed…
Jul 19, 2024, 13:27 | Insight
Fadi Haddad: Hyperleukocytosis in Acute myeloid leukemia
Fadi Haddad, Assistant Professor at Leukemia Department at MD Anderson Cancer Center, shared a post…
Jul 19, 2024, 13:19 | Insight
Sanam Loghavi: Optical genome mapping in acute myeloid leukemia
Sanam Loghavi, shared a post on X about a recent paper titled "Optical genome mapping improves…
Jul 14, 2024, 07:11 | Blog
Naveen Pemmaraju: Nitin Jain and Rami Komrokji kick off the US AML-ALL Focus meeting
Naveen Pemmaraju shared a post on X:   . "Superb talks by Nitin Jain on Highlights…
Jun 29, 2024, 16:57 | Insight
MD Anderson Research Highlights: EHA 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in…
Jun 21, 2024, 07:08 | Insight
Hagop Kantarjian: New encouraging secondary HLH treatment by Abhishek Maiti et al.
Hagop Kantarjian shared a post on X: "New encouraging secondary HLH treatment - Abhishek Maiti."…
Jun 19, 2024, 23:09 | Blog
Wei Ying Jen: Very grateful to be standing on the shoulders of giants
Wei Ying Jen, Haematologist and Leukemia Doctor at MD Anderson Cancer Center, shared on X:…
Jun 19, 2024, 21:45 | Insight
Fadi Haddad: Phase 1/2 trial of DSP-5336 menin inhibitor by Naval Daver
Fadi Haddad, Assistant Professor, Leukemia Department at MD Anderson Cancer Center, shared a post on X/Twitter:…
Jun 19, 2024, 08:13 | Blog
Mikkael A. Sekeres: Look at this collection of myeloid malignancy gurus
Mikkael A. Sekeres, Chief of the Division of Hematology at Sylvester Comprehensive Cancer Center, shared a…
Jun 19, 2024, 07:28 | Insight
Naval Daver presents findings of the ENHANCE-3 study at EHA2024 - AML Hub
AML Hub shared the following post on X:    . "CONGRESS EHA2024 | Naval Daver…
Jun 18, 2024, 23:01 | Insight
Dr. Naval Daver presented results of ENHANCE-3 study at EHA2024
Talha Badar shared on X:         . "Dr. Naval Daver: Presented results of…
Jun 18, 2024, 06:04 | Opinion
Joshua Zeidner: Important results from ENHANCE-3 by Naval Daver
Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X: "Disappointing but important results from…
Jun 17, 2024, 07:05 | Societies
15 Posts You Should Not Miss From EHA 2024!
The European Hematology Association (EHA) Hybrid Congress or EHA2024 will took place in Madrid, Spain…
Jun 14, 2024, 03:49 | Insight
Sankalp Arora: Excited to be presenting retrospective data from MD Anderson at EHA24
Sankalp Arora, a Hematology/Medical Oncology Fellow at the MD Anderson Cancer Center, recently shared a…
Jun 2, 2024, 12:11 | Blog
New clinical data being presented at the ASCO from our ongoing KT-253 Phase 1 oncology trial - Kymera Therapeutics
Pearl Freier, Founder of Cambridge BioPartners, shared a post by Kymera Therapeutics on X/Twitter: "…
May 14, 2024, 15:10 | Blog
Naval Daver shares updates on novel emerging therapies in AML - MD Anderson Cancer Center
MD Anderson Cancer Center shared on X: “There’s much more optimism and hope that we…
May 7, 2024, 23:15 | Blog
Chadi Nabhan: Only at the HOPLive24 you could spot Vincent Rajkumar playing guitar while Aaron Goodman attempting to sing
Vivek Subbiah shared the following post by Chadi Nabhan, Medical Director of The University of Chicago…
May 7, 2024, 02:50 | Blog
Mikkael A. Sekeres: Look at these brilliant minds of hematology…and me
Mikkael A. Sekeres, Chief, Division of Hematology at Sylvester Comprehensive Cancer Center, shared a post…
May 7, 2024, 01:32 | Blog
AML session at HOPLive24 - Blood Cancers Today
Blood Cancers Today shared on X/Twitter: "Up next: Naval Daver, Sanam Loghavi, Rami Komrokji, and Mikkael…
Apr 25, 2024, 00:14 | Blog
Anand Patel: Make sure to sign up for Heme Reports next session!
Anand Patel, Assistant Professor of hematology and oncology at UChicago Medicine, shared a post by Heme…
Apr 3, 2024, 15:05 | Career
Sankalp Arora: Received my first Conquer Cancer, the ASCO Foundation Merit Award
Sankalp Arora, Hematology/Oncology fellow at MD Anderson Cancer Center, posted on X/Twitter: "Received my first…
Mar 19, 2024, 15:49 | Blog
Carmelo Gurnari: Naval Daver offers an amazing overview on the big elephant in the room : TP53 MDS
Carmelo Gurnari, Physician and researcher at the Cleveland Clinic, recently shared on X/Twitter: “Naval Daver…
Sep 21, 2023, 19:20 | Blog
Naval Daver: A true honor to deliver the 2023 David Grimwade Memorial Lecture.
Naval Daver, Professor in the Department of Leukemia at MD Anderson Cancer Center, recently shared…
Sep 20, 2023, 23:04 | Blog
Naval Daver: A true honor to deliver the 2023 David Grimwade Memorial Lecture.
Naval Daver, Professor in the Department of Leukemia at MD Anderson Cancer Center, shared a…
Sep 7, 2023, 20:02 | Societies
Naveen Pemmaraju: And SOHO23 week here in Houston Society of Hematology/Oncology begins!
Naveen Pemmaraju, Director of Department of Leukemia at MD Anderson Cancer Center, shared on Twitter:…
Aug 31, 2023, 19:04 | Insight
Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.
Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center, recently…
All: 39 Posts: 1 - 100
Special Coverage